XML 117 R102.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Information - Schedule of Reportable Segments Reconcile of Segment Information (Details) - Operating Segments - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]      
Cost of drugs $ 9,782,109 $ 7,368,426 $ 5,291,630
Cost of services 885,356 797,286 711,304
Other direct costs 725,322 640,075 549,086
Segment selling, general, and administrative expenses 876,298 802,253 737,268
Segment depreciation and amortization expense 134,677 135,778 138,646
Segment EBITDA 776,156 599,952 540,374
Products      
Segment Reporting Information [Line Items]      
Revenues 11,445,777 8,754,282 6,522,450
Services      
Segment Reporting Information [Line Items]      
Revenues 1,464,787 1,317,932 1,168,566
Pharmacy Solutions      
Segment Reporting Information [Line Items]      
Cost of drugs 9,782,109 7,368,426 5,291,630
Other direct costs 725,322 640,075 549,086
Segment selling, general, and administrative expenses 502,042 462,219 426,521
Segment depreciation and amortization expense 107,198 111,103 115,749
Segment EBITDA 543,502 394,665 370,962
Pharmacy Solutions | Products      
Segment Reporting Information [Line Items]      
Revenues 11,445,777 8,754,282 6,522,450
Provider Services      
Segment Reporting Information [Line Items]      
Cost of services 885,356 797,286 711,304
Segment selling, general, and administrative expenses 374,256 340,034 310,747
Segment depreciation and amortization expense 27,479 24,675 22,897
Segment EBITDA 232,654 205,287 169,412
Provider Services | Services      
Segment Reporting Information [Line Items]      
Revenues $ 1,464,787 $ 1,317,932 $ 1,168,566